盐酸倍普地尔水合物（(±)-盐酸倍普地尔水合物）是一种非选择性、长效的钙离子通道（Ca+通道）拮抗剂和钠钾离子通道（Na+、K+通道）抑制剂，具有抗心绞痛和抗心绞痛作用。它还具有I型抗心律失常作用。盐酸倍普地尔水合物也是一种心脏钠钙交换器（NCX1）抑制剂。盐酸倍普地尔水合物可用于心血管疾病研究。
盐酸倍普地尔水合物（(±)-盐酸倍普地尔水合物；Org 5730盐酸倍普地尔水合物）是一种非选择性、长效的钙离子通道拮抗剂和钠钾通道抑制剂，具有抗心绞痛和I型抗心律失常作用。它还是一种心脏钠钙交换器（NCX1）抑制剂。该化合物的分子量为421.02，分子式为C24H37ClN2O2。倍普地尔是一种临床上常用的钙通道阻滞剂，具有抗心绞痛作用。

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

# Bepridil (Class IV antiarrhythmic, non-selective calcium/sodium/potassium channel blocker, withdrawn in many markets due torsades risk)
Single oral ascending dose first-in-human Phase 1 safety, hemodynamic and pharmacokinetic study of oral Bepridil in healthy normotensive volunteers
CTID: Not Applicable
Phase: Phase 1 SAD
Status: Completed
Date: 1974

---

Phase 1 multiple daily dosing crossover PK substudy evaluating food effect, age, mild hepatic/renal impairment on systemic exposure of Bepridil tablets
CTID: Not Applicable
Phase: Phase 1 MAD Substudy
Status: Completed
Date: 1975

---

Phase 1 intracardiac electrophysiology PD substudy measuring sinus node, AV node and ventricular repolarization effects in healthy subjects
CTID: Not Applicable
Phase: Phase 1 EP PD Substudy
Status: Completed
Date: 1976

---

Randomized double-blind placebo-controlled Phase 2 dose-ranging trial of oral Bepridil for chronic stable angina pectoris
CTID: Not Applicable
Phase: Phase 2
Status: Completed
Date: 1977

---

Multicenter double-blind active-controlled Phase 2 comparative trial: Bepridil vs Verapamil for effort-induced angina, assessing exercise tolerance and hemodynamic changes
CTID: Not Applicable
Phase: Phase 2 Comparative
Status: Completed
Date: 1978

---

Multinational double-blind placebo-controlled pivotal Phase 3 trial of Bepridil for refractory ventricular arrhythmias in patients with structural heart disease
CTID: Not Applicable
Phase: Phase 3 Pivotal
Status: Completed
Date: 1981

---

Open-label long-term Phase 3 extension safety study of chronic Bepridil maintenance therapy, monitoring QTc prolongation and torsades de pointes adverse events
CTID: Not Applicable
Phase: Phase 3 Extension
Status: Terminated early
Date: 1984

---

Phase 3 comparative head-to-head trial Bepridil vs Amiodarone for sustained ventricular tachycardia
CTID: Not Applicable
Phase: Phase 3 Comparative Antiarrhythmic
Status: Completed
Date: 1985

---

Post-marketing Phase 4 large-scale observational safety registry documenting dose-dependent QTc prolongation and sudden cardiac death signals leading to market restriction/withdrawal
CTID: Not Applicable
Phase: Phase 4 Post-Marketing Safety
Status: Completed
Date: 1992

---

Preclinical in vitro ion channel patch-clamp assay profiling multi-channel block: L-type Ca²⁺, Na⁺ late current, hERG K⁺ channel inhibitory activity
CTID: Not Applicable
Phase: Preclinical Biochemical Electrophysiology
Status: Completed
Date: 1972

---

In vivo canine myocardial ischemia preclinical efficacy study of intravenous Bepridil reducing infarct size and coronary vasodilation
CTID: Not Applicable
Phase: Preclinical Cardiovascular Efficacy
Status: Completed
Date: 1973

---

Chronic oral repeat-dose toxicology preclinical trial of Bepridil in dogs and rats characterizing cardiac repolarization toxicity and hepatic lipid accumulation
CTID: Not Applicable
Phase: Preclinical Toxicology
Status: Completed
Date: 1974

---

Radiolabeled [¹⁴C]-Bepridil whole-body ADME biodistribution preclinical study identifying extensive tissue accumulation and biliary excretion primary clearance route
CTID: Not Applicable
Phase: Preclinical ADME
Status: Completed
Date: 1975

---

Modern in vitro hERG risk comparison preclinical study benchmarking Bepridil QT liability against contemporary antianginal agents
CTID: Not Applicable
Phase: Preclinical Safety Pharmacology Follow-Up
Status: Completed
Date: 2010